Please login to the form below

Not currently logged in
Email:
Password:

Cell Therapeutics

This page shows the latest Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy. ... The partners are developing it for both β-thalassemia and sickle cell disease (SCD).

Latest news

More from news
Approximately 9 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer, benign gynaecological disorders (marketed). ... Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody

  • Deal Watch November 2016 Deal Watch November 2016

    One piece of unwelcome news this month was from Juno Therapeutics, which announced it had halted a phase 2 trial of JCAR015, its CAR T cell immunotherapeutic, in patients with relapsed ... This is despite some positive news for Juno released at the

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies. ... acquisition - product. 190. Annapurna

  • Pharma deals in August 2015 Pharma deals in August 2015

    Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib. ... Acquisition of Priority Review Voucher. 350. Evotec. Sanofi. Beta cell

  • Pharma deals in June 2015 Pharma deals in June 2015

    Acquisition - business. 1, 153. Juno Therapeutics/ Celgene Corporation. 10-yr immunotherapy collaboration - CAR-T and T Cell Receptor (TCR) technologies; incl Juno's CD19 and CD22 directed CAR-T candidates. ... NewCo formation, collaboration. 760. Unum

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Gamida Cell strengthens leadership team Gamida Cell strengthens leadership team

    Cellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh. ... Alongside Hamermesh, Gamida Cell has appointed Paul Nee (pictured left) as its vice president of marketing.

  • Rubius Therapeutics adds to its board of directors Rubius Therapeutics adds to its board of directors

    Rubius Therapeutics adds to its board of directors. Francis Cuss and Catherine Sohn join the US biotech. ... Alongside Cuss, Catherine Sohn, currently non-executive chairman of BioEclipse Therapeutics, has also joined the biotech’s board.

  • Rubius Therapeutics strengthens senior team Rubius Therapeutics strengthens senior team

    Rubius Therapeutics, a company focused on creating Red-Cell Therapeutics, has bolstered its senior team with the addition of four new hires. ... Chris and the rest of the team will play a pivotal role in bringing the promise of red cell therapeutics to

  • Bone Therapeutics strengthens clinical development team Bone Therapeutics strengthens clinical development team

    Bone Therapeutics strengthens clinical development team. Dr Miguel Forte joins the firm as chief medical officer. ... Thomas Lienard, chief executive officer at Bone Therapeutics, said: “His vast expertise in cell therapy will be a strong asset to our

  • David Epstein joins Flagship Pioneering as executive partner David Epstein joins Flagship Pioneering as executive partner

    In this newly-created position, Epstein will begin working with Rubius Therapeutics, a red blood cell-focused exploratory venture within the Flagship portfolio, as chairman of its board.

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    Training the next generation of biotech leaders. Cell and gene therapy is no longer science fiction. ... society. “ We look at the manufacturing challenges we are facing for emerging healthcare products, such as stratified protein therapeutics and

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics